2010
IMPACT OF INTRAVENOUS HEPARIN ADMINISTERED PRIOR TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION: ANALYSIS FROM THE HORIZONS-AMI TRIAL
Nikolsky E, Mehran R, Dangas G, Lansky A, Rabbani L, Guagliumi G, Kornowski R, Hartmann F, Fahy M, Witzenbichler B, Peruga J, Gambone L, Parise H, Stone G. IMPACT OF INTRAVENOUS HEPARIN ADMINISTERED PRIOR TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION: ANALYSIS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2010, 55: a185.e1729. DOI: 10.1016/s0735-1097(10)61730-5.Peer-Reviewed Original ResearchPrimary percutaneous coronary interventionHORIZONS-AMI trialPercutaneous coronary interventionCoronary interventionAdministeredTrials
2009
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implications